Report      Database

    United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast, Colorectal, Prostate) Infectious Diseases Test (Virology, HPV, HAI, Critical Care) Genetic Test (Blood Screening, Food Pathogen, Tissue Typing HLA)

    Date: 28 Aug, 2017              Type: Diagnostics              Pages: 146

    United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast, Colorectal, Prostate) Infectious Diseases Test (Virology, HPV, HAI, Critical Care) Genetic Test (Blood Screening, Food Pathogen, Tissue Typing HLA)
    • Electronic Access - Single User License
      $1,490.00
    • CD-ROM Mail Delivery
      $1,590.00
    • Hard-copy Mail Delivery
      $1,640.00
    • Electronic Access - Multi User License
      $2,200.00

    Get Free 10% Customization in this Report

    As the evolution of innovative technologies is happening in the field of research and medicine, molecular diagnostics is growing rapidly. United States molecular diagnostics market is projected to surpass US$ 9 billion by 2024. Molecular diagnostics system is one of the hopeful systems that enable automation of extraction of high-quality nucleic acids from a wide variety of sample types and the selection of targeted, individualized treatment options. Molecular diagnostics system offers early disease detection, potentially before symptoms have even occurred.

    In this report United States molecular diagnostics market has been segmented into three major categories: Oncology Test, Infectious Disease Test and Genetic Disease Test. Further, Oncology Test has been segmented into four major categories: Breast Cancer Test, Colorectal Cancer Test, Prostate Cancer Test and Other Cancer Test. Infectious Disease Test has been segmented into four major categories, namely, Virology, HAI, HPV and Critical Care Test and Genetic Test has been segmented into Blood Screening, HLA and Food Pathogen Test.

     

    Request a free sample copy of the report: http://www.renub.com/contactus.php

     

    United State Molecular Diagnostics Market Shares: Overview 

    Our study found that both the Oncology and Infectious Test market have significant market in United States Molecular Diagnostics Market. In Molecular Oncology Test market; Breast cancer dominates the market on the other side in Molecular Infectious Test market; Virology is leading all other segments. While in terms of Tests Volume; Genetics test is leading all way ahead from Infectious and Oncology Test owing to Food Pathogen Test Volume.

    The top players in United States Molecular Diagnostics Market includes several familiar names such as Roche, Hologic, Becton Dickinson, Myraid Genetics, Qiagen and Abbott, Siemens, bioMérieux and Cepheid.

    Renub Research study titled United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast Cancer, Colorectal Cancer, Prostate Cancer, Others) Infectious Diseases (Virology Test, HPV  Test, HAI Test, Critical Care Test) Genetic Test (Blood Screening, Food  Pathogen Test, Tissue Typing HLA Test) provides a comprehensive assessment of the fast–evolving, high–growth United States Molecular Diagnostics Market. This is the 2nd edition of the report published by Renub Research.

    This 146 page report with 87 Figures and 4 Tables studies the United States Molecular Diagnostics from 4 view points: 

    1) Molecular Diagnostics Market and Forecast 
    2) Segments Market & Forecast
    3) Segments Test Volume & Forecast  
    4) Company Molecular Diagnostics Sales & Forecast  


    United States Molecular Diagnostics Market & Test Volume – Application Segment Analysis (2010 – 2024)

    1.    Oncology Test

    a)    Breast Cancer
    b)    Colorectal Cancer
    c)    Prostate Cancer
    d)    Others

    2.    Infectious Diseases

    a)    Virology Test
    b)    HPV Test
    c)    HAI Test
    d)    Critical Care Test

    3.    Genetic Test

    a)    Blood Screening
    b)    Food  Pathogen Test
    c)    Tissue Typing (HLA Test)


    Company Sales Analysis (2010 – 2024)

    1.    Roche
    2.    Abbott
    3.    Myriad Genetics
    4.    BioMerieux
    5.    Qiagen
    6.    Hologic Inc.
    7.    Becton Dickinson
    8.    Siemens
    9.    Cepheid
    10.    Others

     

    Content from Old Report is given below:

    The user can buy this report in Chapters from Purchase by Chapter section given above

     

    United States Molecular Diagnostics Market & Future Forecast to 2018 Overview
     
    Molecular diagnostics is a rapidly–advancing area of research and medicine, with new technologies and applications being added continuously. Molecular diagnostics is the promising area which can transform disease diagnosis, as diagnosis based on symptoms and use of surrogate markers is replaced by genomic and proteomic analysis. This fundamental shift offers the promise for early disease detection, potentially before symptoms have even occurred. 

    United States molecular diagnostic market for 2018 is anticipated to more than double from its current value in 2013. In United States molecular diagnostic market, infectious disease controls the highest market share in 2013. 

    But in terms of test volume food pathogen testing takes the lead pushing infectious disease at number two position. 

    Molecular oncology tests have emerged as a significant rapidly growing market segment. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. United States constitutes the largest regional market for blood screening and blood products. Molecular diagnostics is also starting to emerge as an important tool for HLA Testing, Food Pathogen Detection Testing and other disease areas. 

    In companies market share  Hologic Inc., Myriad Genetics and Becton Dickinson together these 3 companies control more than 50% market share for 2013. However Becton Dickinson is expected to lose its market share gradually and Roche is expected to take its place by 2018. 

     
    United States Molecular Diagnostics Market & Test Volume – Application Segment Analysis (2010 – 2018)

    1. Oncology Testing 
        a) Breast Cancer
        b) Colorectal Cancer
        c) Prostate Cancer
        d) Others

    2. Infectious Diseases
        a) Virology Testing
        b) HPV Testing
        c) HAI Testing
        d) Critical Care Testing

    3. Genetic Testing
    4. Blood Screening
    5. Food  Pathogen Testing
    6. Tissue Typing (HLA Testing)

    United States Molecular Diagnostics – Company Wise Sales Analysis (2010 – 2018)

    1. Roche
    2. Abbott
    3. Myriad Genetics
    4. BioMerieux
    5. Qiagen
    6. Hologic Inc.
    7. Becton Dickinson
    8. Siemens
    9. Cepheid
    10. Others

    Renub Research study titled “United States (USA)-Molecular Diagnostics Market, Test Volume Forecast & Companies” provides a comprehensive assessment of the fast–evolving, high–growth Global Molecular Diagnostics Market. This 128 page report with 87 Figures studies the United States Molecular Diagnostics from 4 view points: 1) Market and Forecast 2) Application Wise Market & Forecast 3) Application Wise Test Volume & Forecast 4) Company Wise Molecular Diagnostics Sales & Forecast  

    Data Sources
     
    This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.
     
    Primary sources include industry surveys and telephone interviews with industry experts. 
     
    Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 100 paid databases. 

    1.    Executive Summary

    2.    United States Molecular Diagnostics Market & Forecast

    3.    United States Molecular Diagnostics Test Volume & Forecast

    4.    United States Molecular Diagnostics Market Share (2010 – 2024)
    4.1    Market Share & Forecast – (Oncology, Infectious, Genetics) Tests

    4.2    Segments Market Share & Forecast – (Breast, Colorectal, Prostate, Other) Cancer, (Virology, HAI, HPV, Critical Care, HLA, Blood Screening, Food Pathogen) Test

    4.3    Company Market Share – (Roche, Abbott, Myriad Genetics, BioMerieux, Qiagen, Hologic Inc., Becton Dickinson,  Siemens, Cepheid, Others)

    5.    United States Molecular Diagnostics Test Volume Share (2010 – 2024)
    5.1    Volume Share & Forecast – (Oncology, Infectious, Genetics) Tests

    6.    Segments – United States Molecular Diagnostics Market (2010 – 2024)
    6.1    Oncology Test Market Share

    6.2    Oncology Test Market
    6.2.1    Breast Cancer Testing Market
    6.2.2    Colorectal Cancer Test Market
    6.2.3    Prostate Cancer Test Market
    6.2.4    Other Cancer Test Market

    6.3    Market Share – Infectious Disease Test

    6.4    Infectious Disease Test Market
    6.4.1    Virology Test Market
    6.4.2    HPV Test Market
    6.4.3    HAI Test Market
    6.4.4    Critical Care Test Market

    6.5    Genetic Test Market Share

    6.6    Genetic Test Market
    6.6.1    Blood Screening Market
    6.6.2    Food Pathogen Test Market
    6.6.3    Tissue Typing (HLA) Test Market

    7.    Segments – United States Molecular Diagnostics Test Volume (2010 – 2024)
    7.1    Oncology Test Volume Share

    7.2    Oncology Test Volume
    7.2.1    Breast Cancer Test Volume
    7.2.2    Colorectal Cancer Test Volume
    7.2.3    Prostate Cancer Test Volume
    7.2.4    Other Cancer Test Volume

    7.3    Infectious Disease Test Volume Share

    7.4    Infectious Disease Test Volume
    7.4.1    Virology Test Volume
    7.4.2    HPV Test Volume
    7.4.3    HAI Test Volume
    7.4.4    Critical Care Test Volume

    7.5    Genetic Test Volume Share

    7.6    Genetic Testing Test Volume
    7.6.1    Blood Screening Test Volume
    7.6.2    Food Pathogen Test Volume
    7.6.3    HLA Test Volume

    8.    Company – United States Molecular Diagnostics Sales & Forecast
    8.1    Roche

    8.2    Abbott Laboratories

    8.3    Myriad Genetics

    8.4    BioMerieux

    8.5    Qiagen

    8.6    Hologic Inc. (Acquired Gen–Probe)

    8.7    Becton Dickinson

    8.8    Siemens

    8.9    Cepheid

    8.10    Others

    9.    Growth Factors
    9.1    Growing Automation

    9.2    Rising Investment in Genomics & Proteomics Research

    9.3    Personalized Medicine Fuels Molecular Diagnostics

    10.    Challenges
    10.1    Regulatory Issues

    10.2    Reimbursement Capabilities

    10.3    Quality Checkpoints, Awareness & Acceptance
     

    List of Figures

    Figure 2‑1: United States – Molecular Diagnostics Market (Million US$), 2010 – 2016
    Figure 2‑2: United States – Forecast for Molecular Diagnostics Market (Million US$), 2017 – 2024
    Figure 2‑3: United States – Molecular Diagnostics Test Volume (Million), 2010 – 2016
    Figure 2‑4: United States – Forecast for Molecular Diagnostics Test Volume (Million), 2017 – 2024

    Figure 3‑1: United States Molecular Diagnostics Market Share (Percent), 2010 - 2016
    Figure 3‑2: United States – Forecast for Molecular Diagnostics Market Share (Percent), 2017 - 2024
    Figure 3‑3: United States Molecular Diagnostics Test Volume Share (Percent), 2010 - 2016
    Figure 3‑4: United States – Forecast for Molecular Diagnostics Test Volume Share (Percent), 2017 - 2024
    Figure 3‑5: United States – Company Wise Molecular Diagnostics Market Share (Percent), 2010 – 2016
    Figure 3‑6: United States – Forecast for Company Wise Molecular Diagnostics Market Share (Percent), 2017 – 2024

    Figure 4‑1: United States – Molecular Diagnostic Oncology Testing Market (Million US$), 2010 – 2016
    Figure 4‑2: United States – Forecast for Molecular Diagnostic Oncology Testing Market (Million US$), 2017 – 2024
    Figure 4‑3: United States – Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2004 – 2016
    Figure 4‑4: United States – Forecast for Molecular Diagnostic Breast Cancer Testing Market (Million US$), 2017 – 2024
    Figure 4‑5: United States – Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2010 – 2016
    Figure 4‑6: United States – Forecast for Molecular Diagnostic Colorectal Cancer Testing Market (Million US$), 2017 – 2024
    Figure 4‑7: United States – Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2004 – 2016
    Figure 4‑8: United States – Forecast for Molecular Diagnostic Prostate Cancer Testing Market (Million US$), 2017 – 2024
    Figure 4‑9: United States – Other Molecular Diagnostic Cancer Testing Market (Million US$), 2004 – 2016
    Figure 4‑10: United States – Forecast for Other Molecular Diagnostic Cancer Testing Market (Million US$), 2017 – 2024
    Figure 4‑11: United States – Infectious Disease Testing Market (Million US$), 2010 – 2016
    Figure 4‑12: United States – Forecast for Infectious Disease Testing Market (Million US$), 2017 – 2024
    Figure 4‑13: United States – Virology Testing Market (Million US$), 2010 – 2016
    Figure 4‑14: United States – Forecast for Virology Testing Market (Million US$), 2017 – 2024
    Figure 4‑15: United States – HPV Testing Market (Million US$), 2010 – 2016
    Figure 4‑16: United States – Forecast for HPV Testing Market (Million US$), 2017 – 2024
    Figure 4‑17: United States – HAI Testing Market (Million US$), 2010 – 2016
    Figure 4‑18: United States – Forecast for HAI Testing Market (Million US$), 2017 – 2024
    Figure 4‑19: United States – Critical Care Testing Market (Million US$), 2010 – 2016
    Figure 4‑20: United States – Forecast for Critical Care Testing Market (Million US$), 2017 – 2024
    Figure 4‑21: United States – Genetic Testing Market (Million US$), 2010 – 2016
    Figure 4‑22: United States – Forecast for Genetic Testing Market (Million US$), 2017 – 2024
    Figure 4‑23: United States – Blood Screening Market (Million US$), 2006 – 2016
    Figure 4‑24: United States – Forecast for Blood Screening Market (Million US$), 2017 – 2024
    Figure 4‑25: United States – Food Pathogen Testing Market (Million US$), 2010 – 2016
    Figure 4‑26: United States – Forecast for Food Pathogen Testing Market (Million US$), 2017 – 2024
    Figure 4‑27: United States – HLA Testing Market (Million US$), 2008 – 2016
    Figure 4‑28: United States – Forecast for HLA Testing Market (Million US$), 2017 – 2024

    Figure 5‑1: United States – Oncology Test Volume (Million), 2010 – 2016
    Figure 5‑2: United States – Forecast for Oncology Test Volume (Million), 2017 – 2024
    Figure 5‑3: United States – Breast Cancer Test Volume (Million), 2004 – 2016
    Figure 5‑4: United States – Forecast for Breast Cancer Test Volume (Million), 2017 – 2024
    Figure 5‑5: United States – Colorectal Cancer Test Volume (Million), 2010 – 2016
    Figure 5‑6: United States – Forecast for Colorectal Cancer Test Volume (Million), 2017 – 2024
    Figure 5‑7: United States – Prostate Cancer Test Volume (Million), 2004 – 2016
    Figure 5‑8: United States – Forecast for Prostate Cancer Test Volume (Million), 2017 – 2024
    Figure 5‑9: United States – Other Cancer Test Volume (Million), 2004 – 2016
    Figure 5‑10: United States – Forecast for Other Cancer Test Volume (Million), 2017 – 2024
    Figure 5‑11: United States – Infectious Disease Test Volume (Million), 2010 – 2016
    Figure 5‑12: United States – Forecast for Infectious Disease Test Volume (Million), 2017 – 2024
    Figure 5‑13: United States – Virology Test Volume (Million), 2010 – 2016
    Figure 5‑14: United States – Forecast for Virology Test Volume (Million), 2017 – 2024
    Figure 5‑15: United States – HPV Test Volume (Million), 2010 – 2016
    Figure 5‑16: United States – Forecast for HPV Test Volume (Million), 2017 – 2024
    Figure 5‑17: United States – HAI Test Volume (Million), 2010 – 2016
    Figure 5‑18: United States – Forecast for HAI Test Volume (Million), 2017 – 2024
    Figure 5‑19: United States – Critical Care Test Volume (Million), 2010 – 2016
    Figure 5‑20: United States – Forecast for Critical Care Test Volume (Million), 2017 – 2024
    Figure 5‑21: United States – Genetic Testing Test Volume (Million), 2010 – 2016
    Figure 5‑22: United States – Forecast for Genetic Testing Test Volume (Million), 2017 – 2024
    Figure 5‑23: United States – Blood Screening Test Volume (Million), 2006 – 2016
    Figure 5‑24: United States – Forecast for Blood Screening Test Volume (Million), 2017 – 2024
    Figure 5‑25: United States – Food Pathogen Test Volume (Million), 2010 – 2016
    Figure 5‑26: United States – Forecast for Food Pathogen Test Volume (Million), 2017 – 2024
    Figure 5‑27: United States – HLA Test Volume (Million), 2008 – 2016
    Figure 5‑28: United States – Forecast for HLA Test Volume (Million), 2017 – 2024

    Figure 6‑1: Roche – United States Molecular Diagnostic Sales (Million US$), 2008 – 2016
    Figure 6‑2: Roche – Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 – 2024
    Figure 6‑3: Abbott Laboratories – United States Molecular Diagnostic Sales (Million US$), 2010 – 2016
    Figure 6‑4: Abbott Laboratories – Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 – 2024
    Figure 6‑5: Myriad Genetics – United States Molecular Diagnostic Sales (Million US$), 2007 – 2016
    Figure 6‑6: Myriad Genetics – Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 – 2024
    Figure 6‑7: Biomerieux – United States Molecular Diagnostic Sales (Million US$), 2010 – 2016
    Figure 6‑8: Biomerieux – Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 – 2024
    Figure 6‑9: Qiagen – United States Molecular Diagnostic Sales (Million US$), 2010 – 2016
    Figure 6‑10: Qiagen – Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 – 2024
    Figure 6‑11: Hologic–Gen–Probe – United States Molecular Diagnostic Sales (Million US$), 2010 – 2016
    Figure 6‑12: Hologic–Gen–Probe – Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 – 2024
    Figure 6‑13: Becton Dickinson – United States Molecular Diagnostic Sales (Million US$), 2010 – 2016
    Figure 6‑14: Becton Dickinson – Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 – 2024
    Figure 6‑15: Siemens – United States Molecular Diagnostic Sales (Million US$), 2008 – 2016
    Figure 6‑16: Siemens – Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 – 2024
    Figure 6‑17: Cepheid – United States Molecular Diagnostic Sales (Million US$), 2010 – 2016
    Figure 6‑18: Cepheid – Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 – 2024
    Figure 6‑19: Others – United States Molecular Diagnostic Sales (Million US$), 2010 – 2016
    Figure 6‑20: Others – Forecast for United States Molecular Diagnostic Sales (Million US$), 2017 – 2024

    Figure 7‑1: United States – Investment in the Human Genome Project (Billion US$), 2003, 2012
     

     

    List of Tables

    Table 3‑1: United States – Molecular Diagnostics Application Market Share (Percent), 2010 – 2016
    Table 3‑2: United States – Forecast for Molecular Diagnostics Application Market Share (Percent), 2017 – 2024
    Table 3‑3: United States – Molecular Diagnostics Application Test Volume Share (Percent), 2010 – 2016
    Table 3‑4: United States – Forecast for Molecular Diagnostics Application Test Volume Share (Percent), 2017 – 2024

     

    • Description
      Price
    • Chapter 1 & 2     Pages : 7
      $350
    • Chapter 3     Pages : 7
      $600
    • Chapter 4     Pages : 27
      $500
    • Chapter 5     Pages : 28
      $500
    • Chapter 6     Pages : 26
      $500
    • Chapter 7     Pages : 18
      $300
    • Chapter 8     Pages : 7
      $300

    Related Products